Loading...

PE/Cyanine7 anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6pt7_PEslashCy7
C57BL/6 splenocytes were stained with CD8 (clone 53-6.7) PE/Cyanine7 and CD3 FITC.
  • 53-6pt7_PEslashCy7
    C57BL/6 splenocytes were stained with CD8 (clone 53-6.7) PE/Cyanine7 and CD3 FITC.
Compare all formats See PE/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
100721 25 µg 68 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100722 100 µg 198 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Additional Product Notes

BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Calabrese DR, et al. 2020. J Clin Invest. . PubMed
  2. Jarick KJ, et al. 2018. Front Immunol. 9:1468. PubMed
  3. Seo JB, et al. 2019. Nat Metab. 1:86. PubMed
  4. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  5. Vella JL, et al. 2021. Life Sci Alliance. 4:. PubMed
  6. Lechuga-Vieco AV, et al. 2020. Sci Adv. 6:eaba5345. PubMed
  7. Chappaz S, et al. 2021. Cell Reports. 36(3):109430. PubMed
  8. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
  9. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  10. Wu N, et al. 2020. Cell Rep. 30:1129. PubMed
  11. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  12. Tello‐Lafoz M, et al. 2017. Sci Rep. . 10.1038/s41598-017-16370-w. PubMed
  13. Denk D, et al. 2022. Immunity. 55:2059. PubMed
  14. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  15. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
  16. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  17. Zhang R, et al. 2021. Cell Mol Immunol. 18:1222. PubMed
  18. Ma F, et al. 2020. Cell Death Dis. 1.172222222. PubMed
  19. Baram T, et al. 2021. Cells. 10:. PubMed
  20. Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed
  21. Luo R, et al. 2021. Theranostics. 11:117. PubMed
  22. Hu J, et al. 2021. Sci Adv. 7:. PubMed
  23. Mei S, et al. 2022. Front Immunol. 13:911164. PubMed
  24. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  25. Plumlee CR, et al. 2020. Cell Host Microbe. 29(1):68-82.e5. PubMed
  26. Wu FTH, et al. 2019. Br J Cancer. 120:196. PubMed
  27. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  28. Zhao J, et al. 2019. Nat Commun. 10:899. PubMed
  29. Bowers E, et al. 2018. Nat Med. 24:95. PubMed
  30. Leier A, et al. 2022. Mol Ther Nucleic Acids. 28:261. PubMed
  31. Andreas N, et al. 2021. Arthritis Res Ther. 23:222. PubMed
  32. Alotaibi F, et al. 2021. Front Immunol. 11:584937. PubMed
  33. Snyder LM, et al. 2021. PLoS Pathog. 17:e1009970. PubMed
  34. del Rio ML, et al. 2021. Transl Res. Online ahead of print.. PubMed
  35. Chen WS, et al. 2021. Cell Rep. 37:109974. PubMed
  36. Tan X, et al. 2021. Front Oncol. 11:768222. PubMed
  37. Ma C, et al. 2021. Signal Transduct Target Ther. 6:353. PubMed
  38. Saito S, et al. 2020. Nutrients. 12:. PubMed
  39. Neubert K, et al. 2014. J Immunol. 192:5830. PubMed
  40. Sakthivel P, et al. 2014. PLoS One. 9:100970. PubMed
  41. Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed
  42. Peng Z, et al. 2021. STAR Protocols. 2(2):100595. PubMed
  43. Okuniewska M, et al. 2021. Cell Reports. 36(2):109368. PubMed
  44. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  45. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  46. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  47. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  48. Hung PJ, et al. 2018. Mol Cell. 71:332. PubMed
  49. Cai B, et al. 2021. Mol Cancer. 20:165. PubMed
  50. Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed
  51. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  52. Yi M, et al. 2021. J Hematol Oncol. 14:27. PubMed
  53. Guo Z, et al. 2016. Nat Commun. 7:10307. PubMed
  54. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  55. Liu J, et al. 2012. PLoS One. 7:e44044. PubMed
  56. Nakamura‐Ishizu A et al. 2018. Cell reports. 25(7):1772-1785 . PubMed
  57. Guo HF, et al. 2021. Commun Biol. 4:482. PubMed
  58. Wei M, et al. 2014. Protein Eng Des Sel. 27:289. PubMed
  59. Collinson-Pautz M, et al. 2016. PLoS One. 11:e0164547. PubMed
  60. Amor C, et al. 2020. Nature. 583:127. PubMed
  61. Dumas AA, et al. 2020. EMBO J. 39:e103790. PubMed
  62. Szafran BN, et al. 2021. Chemical Research in Toxicology. 34(6):1556-1571. PubMed
  63. Li J, et al. 2020. Cancer Discov. . PubMed
  64. Wei SC, et al. 2020. Cancer Discov. . PubMed
  65. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  66. Liu H, et al. 2020. Cancer Cell. 37(3):324-339. PubMed
  67. Marchingo JM, et al. 2020. eLife. 9:e53725.. PubMed
  68. Alsaleh G, et al. 2020. Elife. 9: . PubMed
  69. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  70. Yang K, et al. 2022. J Clin Invest. 132:. PubMed
  71. Zebley CC, et al. 2021. Cell Rep. 37:109796. PubMed
  72. Dane EL, et al. 2022. Nat Mater. 21:710. PubMed
  73. Guo W, et al. 2022. J Immunother Cancer. 10:. PubMed
  74. Zhao F, et al. 2022. Front Immunol. 13:873720. PubMed
  75. Wang Y, et al. 2021. Sci Rep. 1.429861111. PubMed
  76. Li J, et al. 2020. Cancer Immunol Res. 0.529166667. PubMed
  77. Köchl R, et al. 2020. Elife. 9:00. PubMed
  78. Sullivan B, et al. 2015. PLoS Pathog. 11:1004588. PubMed
  79. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  80. Wang GZ, et al. 2019. Nat Commun. 10:1125. PubMed
  81. Dar HY, et al. 2018. Sci Rep. 8:2503. PubMed
  82. Daniel CJ, et al. 2022. Mol Cancer Res. 20:1151. PubMed
  83. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  84. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  85. Lehmann M, et al. 2016. J Leukoc Biol. 99: 1057 - 1064. PubMed
  86. Walter F, et al. 2020. PLoS One. 15:e0239369. PubMed
  87. Gong Y, et al. 2020. Cell Metabolism. 33(1):51-64.e9. PubMed
  88. Dar HY, et al. 2018. Bone Rep. 8:46. PubMed
  89. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  90. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  91. Li J, et al. 2018. Immunity. 49:178. PubMed
  92. Domingo–Gonzalez R, et al. 2020. eLife. 9:e56890.. PubMed
  93. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
  94. Taniguchi H, et al. 2022. Cell Rep. 39:110814. PubMed
  95. Progatzky F, et al. 2021. Nature. 599:125. PubMed
  96. Akazawa S, et al. 2021. Diabetologia. 64:878. PubMed
  97. Chin AL, et al. 2021. Nat Commun. 12:5138. PubMed
  98. Mulas F, et al. 2020. Cell Mol Immunol. . PubMed
  99. Wen Y, et al. 2020. Hypertension. 869:75. PubMed
  100. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  101. Pinho S, et al. 2022. Nat Cell Biol. 24:290. PubMed
  102. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  103. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  104. Reese B, et al. 2020. J Immunol. 205:3218. PubMed
  105. Abramowski P, et al. 2014. J Neuroimmunol. 274:111. PubMed
  106. Ariyoshi Y, et al. 2016. Gene Ther. 10.1038/gt.2016.7. PubMed
  107. Deerhake ME, et al. 2021. Immunity. 54(3):484-498.e8. PubMed
  108. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  109. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  110. Cheng Y, et al. 2019. Clin Cancer Res. 25:2621. PubMed
  111. Pietronigro E, et al. 2019. Sci Rep. 9:12055. PubMed
  112. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  113. Tan X, et al. 2021. Sci Adv. 7: . PubMed
  114. Sapra L, et al. 2021. Sci Rep. 11:1807. PubMed
  115. Alameh MG, et al. 2021. Immunity. 54:2877. PubMed
  116. Jorapur A, et al. 2022. PLoS Pathog. 18:e1010200. PubMed
  117. Yang Y, et al. 2022. Elife. 11:. PubMed
  118. Kim S, et al. 2021. Elife. 10:. PubMed
  119. Anger-Góra N, et al. 2021. Oncol Lett. 22:582. PubMed
  120. Li H, et al. 2021. Adv Sci (Weinh). 2001596:8. PubMed
  121. Kyburz A, et al. 2019. J Allergy Clin Immunol. 143:1496. PubMed
  122. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  123. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  124. Xiao L, et al. 2021. Clin Cancer Res. 27:4338. PubMed
  125. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  126. Lang V, et al. 2021. Elife. 10:. PubMed
  127. Yabas M, et al. 2016. PLoS One. 11: 0146774. PubMed
  128. Timilshina M, et al. 2017. PLoS One. 10.1371/journal.pone.0168942. PubMed
  129. Jandke A, et al. 2020. Nat Commun. 3.075694444. PubMed
  130. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  131. Chulpanova DS, et al. 2021. Biology (Basel). 10:. PubMed
  132. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  133. Niderla-Bielinska J, et al. 2021. Int J Mol Sci. :22. PubMed
  134. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  135. Itoga M, et al. 2015. PLoS One. 10: e0123210. PubMed
  136. Kalafati L, et al. 2020. Cell. 183:771. PubMed
  137. Muri J, et al. 2020. eLife. 9:e53627.. PubMed
  138. He J, et al. 2020. Evid Based Complement Alternat Med. 2020:5637507. PubMed
  139. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  140. Nelson CE et al. 2019. Cell Rep. 28(12):3092-3104 . PubMed
  141. Hsu M, et al. 2022. Nat Immunol. 23:581. PubMed
  142. Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed
  143. Zhang S, et al. 2022. Nat Commun. 13:4744. PubMed
  144. Robertson TF, et al. 2021. J Cell Biol. 220:. PubMed
  145. X X, et al. 2016. J Immunol . 197: 1683-1691. PubMed
  146. Gomzikova MO, et al. 2020. Pharmaceutics. 12:00. PubMed
  147. Ligon MM, et al. 2020. Mucosal Immunol. 1.172222222. PubMed
  148. Yu M, et al. 2021. Molecular Cell. 81(6):1216-1230.e9. PubMed
  149. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  150. Emily A Thompson et al. 2019. Cell reports. 26(11):2859-2867 . PubMed
  151. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  152. Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed
  153. Bhatt D, et al. 2021. J Exp Med. 218:. PubMed
  154. Wang D, et al. 2022. EMBO Rep. 23:e53691. PubMed
  155. Schönberger K, et al. 2022. STAR Protoc. 3:101408. PubMed
  156. Kojima H, et al. 2021. Scand J Immunol. 93:e13020. PubMed
  157. Abdelsamed HA, et al. 2020. Nat Immunol. 1.276388889. PubMed
  158. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  159. Baglaenko Y, et al. 2016. PLoS One. 11: 0150515. PubMed
  160. Silva DA, et al. 2019. Nature. 565:186. PubMed
  161. Lee YS, et al. 2019. Sci Adv. 5:eaaw4176. PubMed
  162. Chen Y, et al. 2022. Nat Commun. 13:4468. PubMed
  163. Bell CR, et al. 2022. Nat Commun. 13:2063. PubMed
  164. Xiao Y, et al. 2021. Cell. 184:6037. PubMed
  165. Hoechst B, et al. 2016. J Immunol. 195:1517-1523. PubMed
  166. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  167. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  168. Rouse MD, et al. 2020. Front Microbiol. 11:414. PubMed
  169. Lopes N, et al. 2022. Elife. 11:. PubMed
  170. Tang S, et al. 2022. Virol J. 19:32. PubMed
  171. Pantelidou C, et al. 2022. NPJ Breast Cancer. 8:102. PubMed
  172. Fitzpatrick Z, et al. 2020. Nature. 587:472. PubMed
  173. Liu Q, et al. 2021. Adv Mater. 33:e2102852. PubMed
  174. Sharma R, et al. 2021. J Neuroinflammation. 72:18. PubMed
  175. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  176. Siolas D, et al. 2021. Cell Reports. 36:109578. PubMed
  177. Sheng J, et al. 2021. eLife. 10:00. PubMed
  178. Mykkänen O, et al. 2014. PLoS One. 9:114790. PubMed
  179. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  180. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  181. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  182. Lau P, et al. 2022. Cell Mol Immunol. :. PubMed
  183. Xiao Z, et al. 2022. Mater Today Bio. 15:100297. PubMed
  184. Schmit T, et al. 2022. Cell Rep. 38:110456. PubMed
  185. Wang X, et al. 2022. Elife. 11:. PubMed
  186. Endo-Umeda K, et al. 2021. Sci Rep. 11:22595. PubMed
  187. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  188. Goc J, et al. 2021. Cell. 184:5015. PubMed
  189. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  190. Lai NY, et al. 2020. Cell. 180:33:00. PubMed
  191. Wang X, et al. 2021. Sci Transl Med. 13:. PubMed
  192. Goubet AG, et al. 2021. Cell Death Differ. 28:2276. PubMed
  193. Petty AJ, et al. 2021. JCI Insight. 6:. PubMed
  194. Avgustinova A, et al. 2021. Cell Stem Cell. . PubMed
  195. Ye Y, et al. 2020. Genome Med. 0.557638889. PubMed
  196. Kim SH, et al. 2020. Neoplasia. 1.3375. PubMed
  197. Reinke S, et al. 2020. Cell Reports. 30(8):2501-2511. PubMed
  198. Brenner E, et al. 2020. Nat Commun. 11:1335. PubMed
  199. Tan DQ, et al. 2019. Cell Rep. 26:2316. PubMed
  200. Yáñez A et al. 2017. Immunity. 47(5):890-902 . PubMed
  201. Chen S, et al. 2018. Nat Commun. 9:5298. PubMed
  202. Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
  203. Plaza-Sirvent C, et al. 2021. Front Immunol. 12:705436. PubMed
  204. Fearon AE, et al. 2021. iScience. 24:103143. PubMed
  205. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  206. Aggarwal N, et al. 2021. Cell Rep. 37:110170. PubMed
RRID
AB_312760 (BioLegend Cat. No. 100721)
AB_312761 (BioLegend Cat. No. 100722)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
Spark PLUS UV™ 395 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01.21.2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account